BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » osteoblasts

3 Bullet Thursday – Inducing Bone, Growing Vocal Cords, Solving Muscular Dystrophy

November 19, 2015 By Cade Hildreth (CEO) Leave a Comment

3 Bullet Thursday - Inducing Bone, Growing Vocal Cords, & Solving Duchenne Muscular Dystrophy

Stay alert to the latest and greatest on stem cells.  Enjoy this week’s “3 Bullet Thursday,” a weekly post that we do to update you on interesting and important events within the world of stem cells. 


1. The Ottawa Hospital and the University of Ottawa published a landmark study this week in Nature Medicine identifying that Duchenne muscular dystrophy is actually a stem cell disease. The findings were shocking, because it has always been assumed that the muscle weakness produced by the disease results from defects of the muscle fibres. It is now known that the disease also stems from defects in the function of muscle stem cells, which could lead to new treatment approaches. 

 

2. In a world first, vocal cords that can stretch, vibrate, and make sound were grown in the lab. Could this be early hope for the millions worldwide suffering from impaired vocal cords?
 
3. The most astonishing news of the week came from Dr. Rubin and colleagues, who identified that cytochalasin D can alter gene expression in the nuclei of mesenchymal stem cells (MSCs) and induce them to become osteoblasts (bone cells). What makes this shocking is that cytochalasin D acts to break up the actin cytoskeleton, which theoretically, would terminate a cell’s ability to become a bone cell and prompt it to become a fat cell. However, Dr. Rubin discovered that cytochalasin D instead causes broken up actin to be trafficked into the nuclei of MSCs, where it induces cells to become osteoblasts. This finding that could potentially lead to exciting new methods for growing bone, repairing fractures, or reversing osteoporosis. 

 

Bonus:  In major news yesterday, Merck KGaA announced it had completed its acquisition of Sigma-Aldrich Corporation for $140 per share, a deal valued at $17.0 billion. Merck will now offer 300,000+ products, making it the new behemoth within the $130 billion life science industry. 

Happy Thursday!

 


Want to get this fun weekly update?  Join below and we’ll keep you in the loop, starting next week.

Need advanced market analysis? View our global strategic reports for the stem cell and cord blood industry.


 

Filed Under: Adipose SCs, Cord Blood, HSCs, iPS Cells, MSCs, Neural Stem Cells, Stem Cells Tagged With: 3 bullet thursday, market news, mesenchymal stem cells, osteoblasts, stem cells, vocal cords

Mesenchymal Stem Cell Industry News Round Up | June 2015

June 22, 2015 By Cade Hildreth (CEO) Leave a Comment

Mesenchymal Stem Cell Current Events

The mesenchymal stem cell industry is well-known for its shifting dynamics, including new alliances, new research advances and innovations. Every month there are major new events that affect market participants.

While it may be possible to stay informed about mesenchymal stem cell industry news in your region, it can be more difficult to track changes on a global scale. For that reason, the following is a summary of significant mesenchymal stem cell industry events for June 2015.

[Read more…]

Filed Under: MSCs, Stem Cells Tagged With: adipose-derived stem cells, Ampion, current events, cystic fibrosis, industry news, mesenchymal stem cells, osteoblasts, osteoporosis, Stemedica

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.